For roughly two years, the simplest explanation for the compounded GLP-1 market was regulatory: when a drug is on the FDA shortage list, compounding pharmacies gain latitude to prepare copies that would otherwise be off-limits. Demand vastly exceeded supply, the drugs went on the list, and an industry appeared almost overnight.
That latitude narrows when a shortage is declared resolved. The market, predictably, has proven more durable than the legal basis that created it.
Why this is not a simple story
It would be convenient if the compounded market were straightforwardly bad and the branded market straightforwardly good. It is not that tidy.
The compounded market exists because the branded products are unaffordable to a very large number of Americans who clinically qualify for them, and because Medicare’s structural exclusion has left millions without a covered route. Moralizing at patients about that is not medicine; it is an attempt to make a policy failure into a personal one.
At the same time, the risks are real and they are not evenly distributed.
The dosing hazard specifically
The most consistent safety signal in this market has not been contamination. It has been arithmetic.
Branded pens deliver a fixed dose. Many compounded products arrive as a vial of solution at a concentration the patient must convert into units on an insulin syringe. The failure modes are obvious in hindsight — tenfold errors, confusion between milligrams and units, and instructions that vary between suppliers.
Whatever you are taking, and wherever it came from, keep a dated record of it — product, concentration, dose drawn, lot number, and every symptom with the day it started. In a market where recalls happen and sourcing changes without announcement, an accurate personal log is a genuinely useful safety instrument rather than an administrative chore. Zenday is built for it. A notebook by the fridge is not much worse, provided it actually gets written in.
Questions worth asking any source
- Is this a licensed pharmacy in your state, and can you verify the license independently?
- Is the active ingredient base semaglutide or tirzepatide, not a salt form?
- Where is the API sourced and is there third-party testing you can actually see?
- Is there a named prescriber, and is there a real clinical evaluation?
- Is the dose delivered fixed, or must you calculate it?
A source that cannot answer these in writing has told you something.
What we are watching
The enforcement posture, the litigation, the manufacturers’ own cash-pay pricing — which has moved in response to this market — and whether the policy conversation ever addresses the underlying reason it exists.
The most useful thing anyone can say about compounding is not “don’t.” It is: understand exactly what you are buying, from whom, at what concentration, and with what recourse if something goes wrong.